News about Clinical Trials

Pfizer's ELREXFIO Boosts Progression-Free Survival in Relapsed Multiple Myeloma

Pfizer’s ELREXFIO meets primary endpoint in MagnetisMM-5, showing significant progression-free survival benefit in relapsed/refractory multiple myeloma, with consistent safety and ongoing evaluation of Overall Survival (OS).

Clinical Trials | 01/05/2026 | By News Bureau

Precision BioSciences Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Trial

Precision BioSciences activates its first clinical site at Arkansas Children’s Hospital and begins patient enrollment in the phase 1/2 FUNCTION-DMD trial of PBGENE-DMD for Duchenne muscular dystrophy.

Clinical Trials | 30/04/2026 | By News Bureau

Argo Biopharma Doses First Patient in Phase 1 Trial of siRNA Drug BW-50218

Argo Biopharma doses first patient in Phase 1 trial of BW-50218, an siRNA therapeutic from its RADS platform designed for potent, durable gene silencing with targeted hepatic delivery and improved safety.

Clinical Trials | 29/04/2026 | By News Bureau |  101

Soligenix Reports Phase 3 FLASH2 Interim Results for HyBryte in Cutaneous T-Cell Lymphoma

Soligenix reports Phase 3 FLASH2 interim results for HyBryte in Cutaneous T-Cell Lymphoma, with the study recommended for early termination due to futility.

Clinical Trials | 29/04/2026 | By News Bureau |  103

Cellenkos Inc. Wins US FDA Clearance for Phase 2 Trial of CK0801 in Aplastic Anemia

Cellenkos Inc. receives US Food and Drug Administration (FDA) clearance to initiate a Phase 2 multicentre trial of CK0801, evaluating safety and efficacy of cord blood-derived Tregs in transfusion-dependent aplastic anemia patients.

Clinical Trials | 27/04/2026 | By News Bureau |  142

Thryv Therapeutics Advances THRV-1268 Programme with Phase II/III Trial and FDA Fast Track Status

Thryv Therapeutics initiates Phase II/III clinical testing and secures FDA Fast Track status for THRV-1268, advancing a potential first-in-class therapy for Long QT Syndrome.

Clinical Trials | 27/04/2026 | By News Bureau |  134

Ascletis Pharma Completes US Phase 2 Enrollment for ASC30 GLP-1R Agonist

Ascletis Pharma completes US Phase 2 enrollment for ASC30, an oral GLP-1R agonist for diabetes. The 13-week study evaluates safety, efficacy, and tolerability in 100 patients, with topline results expected in Q3 2026.

Clinical Trials | 27/04/2026 | By News Bureau

ModeX Therapeutics Doses First Patients in Trial of Novel Tetraspecific Therapy for B-Cell Lymphoma

ModeX Therapeutics initiates clinical testing of MDX2003, a next-generation multispecific antibody therapy designed to enhance immune response and improve outcomes in B-cell lymphoma patients.

Clinical Trials | 24/04/2026 | By News Bureau |  106

Mabwell Launches Phase 3 Trial of Nectin-4 ADC 9MW2821 for Triple-Negative Breast Cancer

Mabwell launches Phase 3 study of 9MW2821, the world’s first Nectin-4 ADC for TNBC, marking its fourth pivotal clinical trial.

Clinical Trials | 23/04/2026 | By News Bureau |  154

Roche Reports Strong Phase III Results for Fenebrutinib in Multiple Sclerosis

Roche’s investigational drug fenebrutinib shows significant reduction in relapse rates and disease activity in multiple sclerosis, offering potential for improved long-term outcomes in patients.

Clinical Trials | 23/04/2026 | By News Bureau |  132